Antibacterial Activity of Recombinant Porcine β-Defensin 2

Kuohai Fan,1,8 Yina An,1,8 Zhirui Wang, Wei Yin, Na Sun, Yaogui Sun, Ajab Khan, and Hongquan Li*

1College of Animal Science and Veterinary Medicine, Shanxi Agricultural University, Taigu, Shanxi030801, P.R. China
2Center for Transplantation Sciences, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

*Corresponding author: livets@163.com

INTRODUCTION

Defensins, a kind of antimicrobial peptides (AMPs), having a crucial role in the mammals immune systems that provides protection against potential pathogens. Classic mammalian defensins contains 29 to 45 amino acids, three disulphide bonds that formed by the presence of six cysteine residues and a β-sheet structure (Mcdermott, 2004). Considering the spatial distribution of the six cysteine residues and their disulphide bonds pairing, mammalian defensins are divided into α-, β- and θ-defensins (Selsted and Ouellette, 2005). The defensins have a wide antimicrobial spectrum, with the capacity to repel the assault of diverse infectious agents including viruses, bacteria, parasites and fungi (Peng et al., 2016). Their bactericidal activity depends on the disruption of the bacterial membrane and increase the permeability by forming non-specific electrostatic interactions with the membrane lipid components (Masuda et al., 2018). Moreover, defensins can interact with neutrophils, T cells, macrophages, and epithelial cells that induces inflammatory mediators production such as IL-8, IL-6 and IL-1β, which are involved in the inflammatory reaction (Fusco et al., 2017).

β-defensins, the evolutionarily oldest defensins, consist of 30-45 residues of amino acid that includes 5-12 positively charged residues such as arginine and lysine. Typical structure of β defensins composed of an alpha helix with three beta sheets (Huang et al., 2015). The β-defensins are either constitutively expressed or induced in the skin and the mucosal surfaces of airways, digestive tract, and urogenital tract for inflammatory and infectious diseases (Elahi et al., 2006; Sang et al., 2006). Host defence peptides, enhances the total immune response including both innate as well as adaptive immunity, enhances chemoattraction of both antigen presenting and phagocytic cells, regulate host cytokine response, effect the function of both B and T lymphocytes including activation of the B-cells and production of antibodies, and function of the cytotoxic T-cell, natural killer cells and T helper cells (Allaker, 2008).

ARTICLE HISTORY

Received: September 03, 2018
Revised: December 03, 2018
Accepted: December 12, 2018
Published online: March 07, 2019

Key words:
rpBD-2
Antimicrobial activity
Expression
Pichia pastoris
Purification

ABSTRACT

To express and purify the recombinant porcine β-defensin 2 (rpBD-2) using yeast Pichia Pastoris expression system and in vitro characterization of its antibacterial activity, rpBD-2 was expressed and then purified using methylotrophic yeast Pichia Pastoris expression system. To assess its antimicrobial activity against Escherichia coli, Salmonella paratyphi A, Pseudomonas aeruginosa, Staphylococcus epidermidis, Staphylococcus aureus, Bacillus pumilus, and Bacillus subtilis, liquid growth inhibition assay was used. The antibacterial activity was further kinetically evaluated against representative bacterial strains Es. coli and S. aureus. The hemolysis activity of rpBD-2 was also checked against porcine erythrocytes. rpBD-2 was expressed and purified successfully using yeast Pichia Pastoris expression system. The yield of final product was 9 mg per liter of the harvested supernatant. rpBD-2 possessed antimicrobial activity against E. coli, S. aureus, S. epidermidis, B. subtilis, and B. pumilus at 33.3-66.6 μM and killed all E. coli and S. aureus within 30 min. Negligible hemolytic activity was observed against porcine erythrocytes. We have successfully developed rpBD-2 as an effective antibacterial peptide against both gram-positive and negative bacteria. rpBD-2 will be a potential novel therapeutic agent against bacterial infection.

©2018 PVJ. All rights reserved

To Cite This Article: Fan K, An Y, Wang Z, Yin W, Sun N, Sun Y, Khan A and Li H, 2019. Antibacterial activity of recombinant porcine β-defensin 2. Pak Vet J, 39(3): 411-415. http://dx.doi.org/10.29261/pakvetj/2019.030
So far, β-defensins have been reported for pigs only (Sang et al., 2006; Sang and Blecha, 2009), and 29 β-defensin gene-like sequences were identified in the porcine genome (Min-Kyeung et al., 2012). β-defensin 2, as a member of the β-defensin family, is expressed in the porcine intestines and is speculated to be the porcine orthologue of human β-defensin 1 (Sang et al., 2006; Veldhuizen et al., 2007). The porcine β-defensin 2 shows preferentially attack gram-positive and negative as well as multi-resistant bacteria, which indicate that β-defensin 2 has a crucial role in the innate immune response of porcine intestine (Veldhuizen et al., 2008). It has been shown that, administration of β-defensin 2 ameliorated signs and symptoms of inflammation, maintained the integrity of the intestinal mucosal barrier (Han et al., 2015), promoted the piglet growth, increased average daily feed intake and in the duodenum and jejunum increase in the intestinal villus height that causes gain in their average daily and overall body weight and reduced diarrhea incidence of the piglets (Peng et al., 2016; Xu et al., 2016). In addition, the porcine β-defensin 2 could prevent the infection of bacteria from pigs (Yang et al., 2015; Tang et al., 2016). These results demonstrate that β-defensin 2 could be an alternative to the traditional antibiotic feed or novel therapeutic drugs for intestinal infections of pigs.

Our previous study has proved that porcine β-defensins-2 over-expressed in lungs and intestine of pigs infected by Porcine respiratory and reproductive syndrome virus. The aim of this study is to establish a Pichia Pastoris expression system for producing the recombinant porcine β-defensins-2 (rpBD-2), to investigate the antibacterial effect and hemolytic action of rpBD-2 in vitro.

MATERIALS AND METHODS

Plasmid construction: The pBD-2 mRNA sequence was obtained from the National Center for Biotechnology Information (Accession: AY506573.1). The Invitrogen (Shanghai, China), synthesized the XhoI and EcoRI sites carrying codon-optimized pBD-2 DNA. At the C-terminus Six histidines (6x His tag) were added, for facilitation of downstream purification. Using XhoI+EcoRI and Gel Extraction Kit (OMEGA bio-tek, Georgia, USA) to cut the synthesized pBD-2 and extract it respectively. The extracted product was cloned into digested pwPICZalpha vector (XhoI- pBD-2 -EcoRI).

Expression and Purification of protein: The detailed protocols used for the Expression and Protein Purification was as previously described by Fan et al. (2016).

Western blotting: The purified rpBD-2 was treated with non-reducing and reducing loading buffer, separated by electrophoresis through SDS-PAGE, Commassie Blue Fast Staining and electro-transferred onto a polyvinylidene fluoride (PVDF) membrane (Millipore, Massachusetts, USA) at 60 V. Using nonfat dry milk (5%) in Tris-buffered saline (1X) and 0.02% Tween 20 (TBST) with shaking for 1 h to block the membrane and then at room temperature, incubated the membrane for 2 h with shaking using mouse anti-His monoclonal antibody (1:500) (BGI, Beijing, China). Washed three times with TBST, the membrane was again incubated for 1 h and at 37°C with shaking using rabbit anti-mouse immunoglobulin G (IgG)-horseradish peroxidase (HRP) (1:10,000) (CWBO, Beijing, China). Following the manufacturer’s instruction, electrochemiluminescence (ECL) (CWBO, Beijing, China) was used for the detection of proteins.

Antimicrobial activity assay: The rpBD-2 antimicrobial activity was assessed against a panel of microorganisms including Escherichia coli, Pseudomonas aeruginosa, Salmonella paratyphi A, Staphylococcus epidermidis and aureus, Micrococcus luteus, Bacillus pumilus and subtilis. Liquid growth inhibition assays were used to determine the minimal bactericidal concentration (MBC) and minimal growth inhibition concentration (MIC) as previously described (Peng et al., 2010; Haidong et al., 2013). Shortly, using PBS (pH 7.4) to dilute the bacteria in to 1 × 10⁶ CFU. Composition of the assay mixture was, diluted bacterial suspension (30 µL), diluted purified peptide (50 µL) and culture media (20 µL). After incubation at 30°C and for 24 h, MIC was calculated as the lowest peptide concentration yielding no detectable growth. At 37°C the aliquots mixtures were then plated for 24 h on the corresponding agar plates and the MBC value was determined as the lowest concentration that killed more than 99.9% of bacteria. Every assay was performed in triplicate.

Time-kill curve studies: As previously described (Haidong et al., 2013), using E. coli and S. aureus bactericidal or bacteriostatic effect was determined and as mentioned above, 66.65 µM rpBD-2 was incubated with the bacteria. From the mixture, 5 µL at various time points was taken, diluted serially using PBS (pH 7.4), plated on nutrition broth agar, at 37°C incubated for 24 h and then counted the colonies. Relative to the CFU obtained in the control (100% CFU at 0 min), the % CFU was calculated.

Hemolytic assay: Using heparinized tube, collect Porcine fresh blood, centrifuged for 10 min at 800 g, using cold PBS (pH 7.4), gently washed the pellet three times, resuspended and adjusted the concentration to 8%. Using 96-well microtiter plate, erythrocyte suspension (100 µL) was added along with different concentrations of rpBD-2 solution to each well and incubated for 1 h at 37°C. Triton-X 100 (0.2%) and PBS were used as positive and negative controls respectively. After centrifugation (for 10 min at 1000 g), the released supernatant hemoglobin was measured by microplate reader (ELX808; Gene Co., Ltd., Hong Kong, China) at 490 nm (Yan et al., 2012).

RESULTS

Expression and purification of the rpBD-2: rpBD-2 was cloned and expressed in yeast Pichia Pastoris X33 strain. For the first step of purification, ProteinIso™ Ni-NTA resin was used. As shown in Fig. 1, most of the target protein was eluted with 500 mM imidazole. Based on the calculated PI=9.10, a strong cation exchange resin Poros® 50 HS was chosen for the 2nd step of purification. The pure soluble rpBD-2 was eluted with 200 mM sodium
borate (Fig. 2). SDS-PAGE analysis revealed the dispersed bands under non-reducing condition. A single band was observed under the reducing condition with both SDS gel and Western blot analysis (Fig. 3). Taken together, using yeast Pichia Pastoris expression system, rpBD-2 was successfully expressed. More than 95% of purified rpBD-2 was obtained following two steps purifications. The final yield was 9 mg per liter of the original harvested supernatant. The data demonstrated that the disulfide bonds were formed between the rpBD-2 molecules.

**Antimicrobial activity analysis of the rpBD-2:** Minimum bactericidal concentration (MBC) and Minimal inhibitory concentration (MIC) assays were performed to assess the antimicrobial activity of the rpBD-2 against five Gram-positive bacterial strains (S. epidermidis, S. aureus, B. subtilis, B. pumilus and M. luteus) and eight strains of bacteria including three Gram-negative bacterial strains (E. coli, P. aeruginosa and S. paratyphi A) As shown in Table 1. Antimicrobial activity of rpBD-2 was observed against one Gram-negative bacterial strain, E. coli (MIC 33.3-66.6 µM, MBC >66.6 µM) and four Gram-positive bacterial strains including S. aureus (MIC 33.3-66.6 µM, MBC 33.3-66.6 µM), S. epidermidis (MIC 33.3-66.6 µM, MBC 33.3-66.6 µM), B. subtilis (MIC 33.3-66.6 µM, MBC 33.3-66.6 µM) and B. pumilus (MIC 33.3-66.6 µM, MBC >66.6 µM). rpBD-2 is highly effective against Gram-positive bacteria compared to Gram-negative one.

The bactericidal activity of rpBD-2A was further kinetically evaluated using a highly sensitive Gram-positive bacterial strain S. aureus and a Gram-negative bacterial strain E. coli. To assess the bactericidal activity of this peptide, plating cultures and after incubation at 37°C for 24 h, CFUs were counted that show that approximately 35, 59 and 100% E. coli and approximately 30, 77 and 100% S. aureus were killed by purified rpBD-2 after 10, 20 and 30 min of incubation respectively (Fig. 4).

**Hemolytic activity of the rpBD-2:** The hemolytic activity of rpBD-2 was assessed by the level of breakdown of porcine erythrocytes. In Fig. 5, porcine erythrocytes weak hemolysis was observed at 33.33 µM. Hemolysis was less than 10% at 66.65 µM, at which it exhibited potent antibacterial activity. rpBD-2, hence had very low hemolytic activity and suitable to be use as an antibiotic.

**DISCUSSION**

Defensins are cysteine-rich cationic AMPs with a molecular weight between 2 to 6 kDa, having a broad spectrum antimicrobial activity that kills bacteria, viruses and fungi. Furthermore, defensins have the ability of linking innate and adaptive immune responses in higher organisms. It acts as a signaling molecule in the immune system and also as a chemotactic agent for T lymphocytes and immature dendritic cells. So, defensins have both anti-microbial and immunomodulatory effect (Choi et al., 2012).
Fig. 5: The hemolytic activity of the rpBD-2 was measured by the release of hemoglobin from porcine erythrocytes. The erythrocytes were incubated with different concentrations of rpBD-2 at 37°C for 60 min. 0.2% Triton-X 100 and PBS were used as positive and negative controls, respectively.

### Table 1 Antimicrobial activity of the rpBD-2

| Microorganisms              | CMCC no. | MIC (b-e μM) | MBC (d-e μM) |
|----------------------------|----------|--------------|--------------|
| Escherichia coli           | 44102    | 33.3-66.6    | 33.3-66.6    |
| Salmonella paratyphi A     | (B) 50001| NT           | NT           |
| Pseudomonas aeruginosa     | (B) 10104| NT           | NT           |
| Staphylococcus aureus      | 26003    | 33.3-66.6    | 33.3-66.6    |
| Staphylococcus epidermidis | (B) 26069| 33.3-66.6    | 33.3-66.6    |
| Bacillus subtilis          | 63501    | 33.3-66.6    | 33.3-66.6    |
| Bacillus pumilus           | (B) 63202| 33.3-66.6    | NT           |
| Micrococcus luteus         | (B) 28001| NT           | NT           | a. National Center For Medical Culture Collections number. b, c, MIC values are expressed as the interval of concentration b-c μM, where b is the highest concentration tested at which microbial growth can be observed, and c is the lowest concentration yielding no detectable microbial growth (n=3). d, e, MBC values are expressed as the interval of concentration d-e μM, where d is the same mean as the b, and e is the lowest concentration tested that inhibited microorganism growth or that killed more than 99.9% of the microorganisms (n=3). f. Not tested.

In the recent study, we expressed porcine β-defensin 2 using *Pichia Pastoris* expression system and tested its antibacterial and hemolytic activity in vitro, successfully. It was demonstrated that the recombinant porcine β-defensin 2 can not only inhibit the growth of bacteria (Table 1) but also has low hemolytic activity to porcine erythrocytes (Fig. 5) that make it very suitable to be used as an antibiotic in future.

Previous studies have shown that porcine β-defensin 2 can be expressed in *Pichia Pastoris* but only an inhibitory effect on *Salmonella choleraesuis* A500 strain has been studied (Hu *et al.*, 2011), while porcine β-defensin 2, which was expressed in fusion with porcine IFN-γ, shows no antibacterial activity (Zhang *et al.*, 2010). (Li *et al.*, 2013) obtained a histidine-tagged β-defensin 2 using an *E. coli* expression system, which has a bacteriolytic effect on *Escherichia coli* and *Staphylococcus aureus*. In this study, the histidine-tagged β-defensin 2 was obtained with the *Pichia Pastoris* expression system (Fig. 3). The purified recombinant β-defensin 2 has been tested for the antibacterial and hemolytic activity. The results showed that it has not only an inhibitory effect on the growth of *Escherichia coli* and *Staphylococcus aureus* but can also inhibit the growth of *Staphylococcus epidermidis, Bacillus subtilis* and *Bacillus pumilus* (Table 1) which showed that recombinant β-defensin 2 has a wide range antibacterial activity.

β-defensin 2 performs antimicrobial actions by inserting its C-terminal into the cell membrane. Long peptide chains of the cell membrane connected with the C-terminal, that affect the formation of correct spatial structure of the cell membrane, thereby affecting the broad function and structure of the membrane (Zhang *et al.*, 2010). Since β-defensin 2 has not been purified from pigs to date, whether the histidine tag affects the antibacterial activity of recombinant β-defensin 2, needs to be explored in future.

Conclusions: rpBD was expressed and purified successfully using yeast *Pichia Pastoris* expression system. rpBD-2 is an effective antibiotic peptide against all tested Gram-positive and Gram-negative bacteria. Only weak hemolytic activity was observed.

Authors contribution: KF designed the experiment, done the expression and purification part of protein. YA did the antimicrobial and hemolytic activity analysis. AK helps in the write up and editing of the manuscript. All authors statistically analyzed, discussed, critically revised the contents and approved the final manuscript.

REFERENCES

Allaker P. 2008. Host defence peptides—a bridge between the innate and adaptive immune responses. Trans R Soc Trop Med Hyg 102:3–4.

Choi K, Le T, Nguyen T, et al., 2012. Genome-level identification, gene expression, and comparative analysis of porcine β-defensin genes. BMC Genet 13:98.

Elahi S, Buchanan M, Aatabhoku S, et al., 2006. The host defense peptide beta-defensin 1 confers protection against *Bordetella pertussis* in newborn piglets. Infect Immun 74:2338-52.

Fan K, Li H, Wang Z, et al., 2016. Expression and purification of the recombinant porcine nik-lysin in pichia pastoris and observation of anticancer activity in vitro. Prep Biochem Biotechnol 46:63-70.

Fusco A, Savio V, Cammarota M, et al., 2017. Beta-defensin-2 and beta-defensin-3 reduce intestinal damage caused by *Salmonella typhimurium* modulating the expression of cytokines and enhancing the probiotic activity of enterococcus fecium. J Immunol Res 2017:1-9.

Haidong U, Chen B, Peng H, et al., 2013. Molecular cloning, recombinant expression, and antimicrobial activity of ee-hepcidin3, a new four-cysteine hepcidin isoform from epinephelus coioiesi. Biosci Biotechnol Biochem 77:103-10.

Han F, Zhang H, Xia X, et al., 2015. Porcine β-defensin 2 attenuates inflammation and mucosal lesions in dextran sodium sulfate-induced colitis. J Immunol 194:1892.

Huang X, Gao Y, Zhao J, et al., 2015. Antimicrobial characterization of site-directed mutagenesis of porcine beta defensin 2. PLoS One 10:e0118170.

Hu H, Yu B, He Q, et al., 2011. Expressing of porcine beta-defensin-2 mature peptide in the yeast. Acta Microbiol Sin 51:704-9.

Li C, Zhao Y, Song X, et al., 2013. Molecular cloning, expression and characterization of the porcine β defensin 2 in E. coli. Protein Pept Lett 20:715-23.

Masuda N, Mantani Y, Yuasa H, et al., 2018. Immunohistochemical study on the distribution of β-defensin 1 and β-defensin 2 throughout the respiratory tract of healthy rats. J Vet Med Sci 80:395-404.

Mcdermott and Alison M, 2004. Defensins and other antimicrobial peptides at the ocular surface. Ocul Surf 2:229.

Min-Kyeong C, Le T, Truong D, et al., 2012. Genome-level identification, gene expression and comparative analysis of porcineβ-defensin genes. BMC Genet 13:1-10.
Peng H, Yang M, Huang S, et al., 2010. Soluble expression and purification of a crab antimicrobial peptide scygonadin in different expression plasmids and analysis of its antimicrobial activity. Protein Expr Purif 70:109-15.

Peng Z, Wang A, Xie L, et al., 2016. Use of recombinant porcine β-defensin 2 as a medicated feed additive for weaned piglets. Sci Rep 6:26790.

Sang Y and Blecha F, 2009. Porcine host defense peptides: expanding repertoire and functions. Dev Comp Immunol 33:334.

Sang Y, Patil A, Zhang G, et al., 2006. Bioinformatic and expression analysis of novel porcine β-defensins. Mamm Genome 17:332-9.

Selsted E and Ouellette AJ, 2005. Mammalian defensins in the antimicrobial immune response. Nat Immunol 6:551.

Tang Z, Xu L, Shi B, et al., 2016. Oral administration of synthetic porcine beta-defensin-2 improves growth performance and cecal microbial flora and down-regulates the expression of intestinal toll-like receptor-4 and inflammatory cytokines in weaned piglets challenged with enterotoxigenic Escherichia coli. Anim Sci J 87:1258-66.

Veldhuizen J, Van A, Tersteeg H, et al., 2007. Expression of beta-defensins pdβ-1 and pdβ-2 along the small intestinal tract of the pig: lack of upregulation in vivo upon salmonella typhimurium infection. Mol Immunol 44:276-83.

Veldhuizen J, Rijnders M, Claassen A, et al., 2008. Porcine beta-defensin 2 displays broad antimicrobial activity against pathogenic intestinal bacteria. Mol Immunol 45:386-94.

Xu J, Zhong F, Zhang Y, et al., 2016. Construction of Bacillus subtilis strain engineered for expression of porcine β-defensin-2/cecropin p1 fusion antimicrobial peptides and its growth-promoting effect and antimicrobial activity. Asian-Australasian J Anim Sci 30:576.

Yang X, Cheng Y, Tan M, et al., 2015. Overexpression of porcine beta-defensin 2 enhances resistance to actinobacillus pleuropneumoniae infection in pigs. Infect Immun 83:2836-43.

Yan J, Wang K, Chen R, et al., 2012. Membrane active antitumor activity of nk-18, a mammalian nk-lysin-derived cationic antimicrobial peptide. Biochimie 94:184-91.

Zhang D, Sun L, Yang L, et al., 2010. Fusion expression and bioactivity comparison of porcine beta-defensin-2 and porcine interferon-gamma in Pichia pastoris. Chin J Biotechnol 26:1652-9.